Famotidine MarketSize, Share & Industry Analysis, 2026-2034By FormulationBy TypeBy ApplicationBy Distribution ChannelBy Age Group

Famotidine is a histamine H2-receptor antagonist used to reduce gastric acid secretion in the treatment of gastroesophageal reflux disease, peptic ulcer disease and other acid-related conditions, and is available in prescription and over-the-counter forms including tablets, oral suspension, chewable tablets and injectable formulations. Buyers span hospital and retail pharmacies, physicians treating chronic acid-reflux and ulcer conditions, and individual consumers self-treating heartburn and acid indigestion through over-the-counter purchase. Both branded and generic versions are manufactured and distributed, with generic producers supplying the majority of volume sold through retail and institutional channels.

Growth of 4.33% a year carries the global famotidine market from USD 1.95 billion in 2025 to USD 2.85 billion in 2034. The full series behind that rate covers USD 1.55 billion in 2020, USD 1.87 billion in 2024, USD 2.03 billion in 2026 and USD 2.41 billion in 2030, with 2025 as the base year.

62.05% of 2025 revenue sits in Tablets, worth USD 1.21 billion and rising to USD 1.65 billion at 57.89% by 2034, the largest formulation line in both years. Growth is fastest in Chewable Tablets at 6.26% and slowest in Tablets at 3.53%. Share moves toward Injectables, Oral Suspension and Chewable Tablets and away from Tablets, though no line shrinks in revenue terms.

By type, Generic accounts for 77.95% of 2025 revenue at USD 1.52 billion, reaching USD 2.34 billion and 82.11% by 2034. It is also the fastest-growing line on this axis at 5.54%, so the split concentrates over the period instead of balancing. This axis divides the same revenue as the formulation split instead of adding to it, so the two are read together and never summed.

Geographically, 33.85% of 2025 revenue sits in North America (USD 0.66 billion rising to USD 0.86 billion) ahead of Asia Pacific at 28.21% and USD 0.55 billion. Middle East and Africa is smallest, at 5.64%. Because Asia Pacific and Latin America take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

Behind these figures sit five regions, four formulation lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies, short of a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• The global famotidine market moves from USD 1.55 billion in 2020 to USD 1.95 billion in 2025 and USD 2.85 billion by 2034, the forecast period compounding at 4.33% a year.
• The largest line by formulation is Tablets, worth USD 1.21 billion and 62.05% of revenue in 2025, rising to USD 1.65 billion and 57.89% by 2034.
• At 6.26%, Chewable Tablets grows faster than any other formulation line, moving from USD 0.16 billion and 8.21% of revenue in 2025 to USD 0.26 billion and 9.12% in 2034.
• Against a base case of USD 2.85 billion in 2034, the study also reports a bear case at USD 2.57 billion and a bull case at USD 3.14 billion, with the assumptions behind each set out separately.
• North America holds 33.85% of global revenue in 2025 at USD 0.66 billion, the largest of the five regions tracked, and reaches USD 0.86 billion by 2034.
• The United States accounts for 87.88% of North America in the base year, worth USD 0.58 billion in 2025 and reaching USD 0.75 billion by 2034, the worked country example carried through that region's chapters.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

The global famotidine market is shaped over 2026-2034 by three measurable movements: a change in the formulation mix, a shift in where revenue sits geographically, and the 4.33% rate carrying the total.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Chewable Tablets grows faster than Tablets. The widest spread on the formulation axis is between Chewable Tablets at 6.26% and Tablets at 3.53%. By 2034 the two sit at 9.12% and 57.89% of revenue, against 8.21% and 62.05% in 2025. In absolute terms Chewable Tablets rises from USD 0.16 billion to USD 0.26 billion, while Tablets rises from USD 1.21 billion to USD 1.65 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Growth concentrates in Asia Pacific and Latin America. Asia Pacific moves from 28.21% of revenue in 2025 to 32.98% in 2034, worth USD 0.55 billion rising to USD 0.94 billion; Latin America moves from 8.21% of revenue in 2025 to 9.12% in 2034, worth USD 0.16 billion rising to USD 0.26 billion. Share moves off the others in turn: North America at 33.85% moving to 30.18%, Europe at 24.1% moving to 22.11%, Middle East and Africa at 5.64% moving to 5.61%, each still growing in revenue terms. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

Fifteen years without a discontinuity. The market moves through USD 1.55 billion in 2020, USD 1.87 billion in 2024, USD 1.95 billion in 2025, USD 2.03 billion in 2026, USD 2.41 billion in 2030 and USD 2.85 billion in 2034. The forecast rate of 4.33% sits against 4.7% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the formulation and regional axes, not by the headline rate.

Chewable Tablets adds the most incremental growth

Separate the 4.33% into its parts and three show up: an already-large base compounding, the formulation mix moving toward its faster lines, and regional growth landing unevenly.

The bear case and what drives it

Where the forecast could be beaten

The total depends on a single line

In North America, 33.85% of global revenue puts 2025 at USD 0.66 billion on the way to USD 0.86 billion by 2034. Among the five regions it ranks first by revenue in both years.

Share settles at 30.18% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The formulation mix reported at global level applies here, with Tablets the largest line at 62.05% of 2025 revenue and Chewable Tablets the fastest-growing at 6.26%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

USD 0.58 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 0.75 billion by 2034. 87.88% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Regional revenue of USD 0.66 billion in 2025 and USD 0.86 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Tablets at 62.05% of 2025 revenue, easing to 57.89% by 2034, and the fastest is Chewable Tablets at 6.26%, from 8.21% to 9.12%. Because the country carries 87.88% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports the United States by formulation separately.

In the United States, famotidine sits under the oversight of the Food and Drug Administration, governed by the Federal Food, Drug, and Cosmetic Act. Prescription strengths require an approved New Drug Application or an Abbreviated New Drug Application for generic entrants, while lower-dose formulations sold without a prescription fall under the FDA's monograph system for over-the-counter acid reducers. Manufacturers must operate under current Good Manufacturing Practice standards and submit to FDA facility inspection. Labeling must carry the Drug Facts panel for OTC packs or full prescribing information for prescription packs, stating indications, dosing, and warnings clearly for the consumer or physician.

Supplier positions in the United States sit on the formulation axis: the country buys the same lines the global market does, in the same order. Tablets, at 62.05% of 2025 revenue, is where the volume sits, and Chewable Tablets, growing at 6.26%, is where position changes hands over the forecast period. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 0.08 billion in 2025, rising to USD 0.11 billion by 2034; 4.1% of global revenue and 12.12% of North America. It is reported separately from the United States across every segmentation axis in the full report.

24.1% of the global famotidine market sits in Europe in 2025, worth USD 0.47 billion on the way to USD 0.63 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Its share moves to 22.11% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The formulation mix reported at global level applies here, with Tablets the largest line at 62.05% of 2025 revenue and Chewable Tablets the fastest-growing at 6.26%. The full report breaks Europe out along every axis and by country.

29.79% of Europe's base-year revenue comes from Germany; USD 0.14 billion, rising to USD 0.19 billion by 2034. 29.79% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 0.47 billion to USD 0.63 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Tablets at 62.05% of 2025 revenue, easing to 57.89% by 2034, and the fastest is Chewable Tablets at 6.26%, from 8.21% to 9.12%. With 29.79% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-formulation revenue for Germany appears on its own in the full report.

Germany regulates famotidine as a medicinal product under the national implementation of European Union pharmaceutical law, with the Federal Institute for Drugs and Medical Devices, known as BfArM, serving as the competent authority alongside the European Medicines Agency for centrally authorized products. A marketing authorization must be secured before sale, granted only after review of quality, safety, and efficacy data. Manufacturing sites must conform to EU Good Manufacturing Practice guidelines, and packaging must carry a German-language package leaflet meeting the labeling requirements set out in the EU medicinal products directive. Pharmacovigilance obligations continue after approval.

Competition in Germany is decided on the formulation axis rather than on geography, since suppliers here sell into the same formulation lines reported globally. Two different problems sit on the same axis: holding Tablets at 62.05% of 2025 revenue, and taking Chewable Tablets while it grows at 6.26%. A supplier weighted toward Europe is competing over a base of USD 0.47 billion in 2025 reaching USD 0.63 billion by 2034, 24.1% of global revenue at the start of that period.

6.15% of global revenue is generated in the United Kingdom; USD 0.12 billion in 2025, reaching USD 0.16 billion in 2034, and 25.53% of Europe.

Within Europe, France accounts for 19.15% of regional revenue and 4.62% of the global total, worth USD 0.09 billion in 2025 and USD 0.13 billion by 2034.

USD 0.55 billion of 2025 revenue is generated in Asia Pacific, 28.21% of the global famotidine market on the way to USD 0.94 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.

Its share rises to 32.98% over the forecast period, because it outgrows the market's 4.33%; the revenue added here is disproportionate to where the region started.

Within the region the formulation split tracks the global one; 62.05% of 2025 revenue in Tablets, fastest growth of 6.26% in Chewable Tablets. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

The largest single market in Asia Pacific is China, at USD 0.18 billion in 2025 and USD 0.3 billion in 2034. 32.73% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 0.55 billion to USD 0.94 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in China follows the formulation mix reported at global level: Tablets is the largest line at 62.05% of 2025 revenue, moving to 57.89% by 2034, while Chewable Tablets grows fastest at 6.26% and takes its share from 8.21% to 9.12%. Because the country carries 32.73% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by formulation for China is reported separately in the full report.

China places famotidine under the authority of the National Medical Products Administration, the body responsible for drug registration nationwide. A supplier must obtain a Drug Registration Certificate before the product may be marketed, supported by data demonstrating quality and clinical safety. Production must take place at facilities holding a valid Good Manufacturing Practice certificate issued under Chinese standards, and imported product is subject to additional customs and registration checks. Packaging and inserts must meet the labeling format set by the Chinese Pharmacopoeia and NMPA guidance, presented in Chinese and covering dosage, contraindications, and storage conditions.

Supplier positions in China sit on the formulation axis: the country buys the same lines the global market does, in the same order. Two different problems sit on the same axis: holding Tablets at 62.05% of 2025 revenue, and taking Chewable Tablets while it grows at 6.26%. The commercial size of that position is USD 0.55 billion in 2025 and USD 0.94 billion by 2034, 28.21% of the global total in the base year.

7.69% of global revenue is generated in India; USD 0.15 billion in 2025, reaching USD 0.28 billion in 2034, and 27.27% of Asia Pacific.

5.13% of global revenue is generated in Japan; USD 0.1 billion in 2025, reaching USD 0.15 billion in 2034, and 18.18% of Asia Pacific.

USD 0.16 billion of 2025 revenue is generated in Latin America, 8.21% of the global famotidine market and reaches USD 0.26 billion by 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

9.12% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 4.33%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Tablets largest at 62.05% of 2025 revenue, Chewable Tablets fastest at 6.26%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

The largest single market in Latin America is Brazil, at USD 0.09 billion in 2025 and USD 0.14 billion in 2034. 56.25% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 0.16 billion in 2025 and USD 0.26 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Brazil buys along the same lines as the market globally; Tablets first at 62.05% of 2025 revenue and 57.89% in 2034, Chewable Tablets fastest at 6.26% on a share moving from 8.21% to 9.12%. Its 56.25% weight in Latin America means those movements carry straight into the regional totals. The full report reports Brazil by formulation separately.

In Brazil, the National Health Surveillance Agency, known as ANVISA, holds authority over famotidine as a pharmaceutical product. Sale requires sanitary registration, granted only once the agency has reviewed manufacturing, quality, and clinical data submitted by the applicant. Manufacturing facilities, whether domestic or foreign, must hold Good Manufacturing Practice certification recognized by ANVISA, and imported batches undergo further verification before release. Labeling must appear in Portuguese, following ANVISA's packaging and package-insert rules, and must state active ingredient content, indications, and warnings in the format the agency prescribes for oral acid-reducing medicines.

Competition in Brazil is decided on the formulation axis rather than on geography, since suppliers here sell into the same formulation lines reported globally. The commercially relevant division is 62.05% of 2025 revenue in Tablets, where the volume is, against 6.26% growth in Chewable Tablets, where share moves. A supplier weighted toward Latin America is competing over a base of USD 0.16 billion in 2025, reaching USD 0.26 billion by 2034 on the trajectory this study models.

Mexico is sized at USD 0.05 billion in 2025, rising to USD 0.08 billion by 2034; 2.56% of global revenue and 31.25% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

5.64% of the global famotidine market sits in Middle East and Africa in 2025, worth USD 0.11 billion with USD 0.16 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Its share moves to 5.61% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The formulation mix reported at global level applies here, with Tablets the largest line at 62.05% of 2025 revenue and Chewable Tablets the fastest-growing at 6.26%. The full report breaks Middle East and Africa out along every axis and by country.

36.36% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.04 billion, rising to USD 0.06 billion by 2034. At 36.36% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 0.11 billion and USD 0.16 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Saudi Arabia buys along the same lines as the market globally; Tablets first at 62.05% of 2025 revenue and 57.89% in 2034, Chewable Tablets fastest at 6.26% on a share moving from 8.21% to 9.12%. Because the country carries 36.36% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Saudi Arabia carries its own formulation breakdown in the full report.

Saudi Arabia regulates famotidine through the Saudi Food and Drug Authority, the national body responsible for pharmaceutical registration and market surveillance. A product must be registered with the authority before distribution, with the applicant demonstrating quality, safety, and manufacturing compliance through dossiers aligned with the authority's own guidelines and, where applicable, Gulf Cooperation Council harmonization standards. Manufacturing sites must hold current Good Manufacturing Practice certification recognized by the authority. Labeling must appear in Arabic alongside English, disclosing dosage, indications, and storage instructions, and must match the registered dossier before any pack reaches pharmacy shelves.

Saudi Arabia does not have a competitive structure of its own; position here is position on the formulation axis reported above. Two different problems sit on the same axis: holding Tablets at 62.05% of 2025 revenue, and taking Chewable Tablets while it grows at 6.26%. The commercial size of that position is USD 0.11 billion in 2025, moving to USD 0.16 billion by 2034 across the forecast period.

Within Middle East and Africa, South Africa accounts for 27.27% of regional revenue and 1.54% of the global total, worth USD 0.03 billion in 2025 and USD 0.05 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Formulation, Type, Application, Distribution Channel, Age Group, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.